Company intelligence

KYTX

Kyverna Therapeutics, Inc. · NASDAQ · Healthcare

Price$7.14+0.14% · +$0.01

Market cap434.08MEquity value

P / E-2.4Trailing ratio

Volume72.88KLatest session

Market data

KYTX price chart

TradingView

Related signals

1 min delayed

Browse public KYTX signals with their source context and measured market impact. Open any signal for its permanent analysis page.

KYTXDec 16, 2025-33.81% since signal

Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Kyverna Therapeutics Inc (KYTX) fell 7.2% to $10.04 in pre-market trading. The decline followed KYTX's announcement of a $100 million offering. Other stocks like Lightwave Logic also experienced significant pre-market drops. Market sentiment appears bearish, influencing multiple biotech stocks today. Overall market futures are lower, impacting investor confidence.

View signal analysis

KYTXDec 15, 2025+15.79% since signal

Kyverna's cell therapy meets main goal of mid-stage study

Kyverna's therapy for a rare disorder met mid-stage study goals. Company shares rose 20% in premarket trading.

View signal analysis

KYTXAug 20, 2025+3.47% since signal

Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026

Kyverna Therapeutics focuses on cell therapies for autoimmune diseases, advancing KYV-101. KYV-101 trials aim for FDA approval for stiff person syndrome and myasthenia gravis. Kyverna has $211.7 million cash, ensuring operational funds through 2027. Analyst expects KYV-101 will be the first CAR-T therapy for autoimmune diseases. William Blair gives KYTX a fair value estimate of $27, indicating strong potential.

View signal analysis

Research